Frontier Pharma Report: Schizophrenia Markets 2018 - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

DX'd - Other
1
4 Likes
2

I am happy cuz its shows early promise in treating negative and cognitive symptoms…!!!

Its unmet need …!!! Yes we need medication for negative and cognitive symptoms…!!!

2 Likes
3

@twinklestars what phase means first in class molecule means …??? first second or third…???

2 Likes
4

Thanks for sharing this @far_cry0 Keep us posted :newspaper:

2 Likes
5

First in class means it is a new mechanism of action, a new treatment target. It doesn’t have anything to do with the phase.

2 Likes
6

Thank you for posting @far_cry0

2 Likes
7

“…majority of these products are small molecules, with a small but notable portion of the pipeline consisting of other molecule types such as cell therapies, peptides and vaccines - none of which are currently present in the schizophrenia market.”

There are 160 products in the pipeline.

@GentleSoul they mention cell therapy

2 Likes
8

Thank you @twinklestars .
Cell therapies, peptides and vaccines are a novelty, I guess.
Gene therapy is another option in the offing.
I guess that even medications with vastly improved safety would be a step forward.

3 Likes
9

Good night from kirtipur guys.

Good morning to U.s…!!

2 Likes
10

@moderators I believe this topic should be in the news section.

3 Likes
11

I read this a couple of days ago. I am really looking forward for something new, for a paradigm shift.

1 Like
12

@twinklestars ive done so many google searches for cell therapy and sz and nothing ever comes up. Lets hope soon enough.

2 Likes
13

Yeah, IDK, I’m not going to purchase this report, but it would be interesting to know who is developing it, if they are.

2 Likes
14

This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.